65,437 trials
Japanese Encephalitis
Primary: Number of Participants With Treatment Emergent Adverse Events Following Vaccination With Either ChimeriVax™ JE or JE Inactivated Mouse Brain Derived Vaccine — 2; 2; 1; 0…
Pulmonary Hypertension
Primary: Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a…
Hypertension
Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg
Conjunctivitis
Primary: Sensitivity and Specificity of RPS Adeno Detector IV Compared to Cell Culture. — 90; 96 percentage of cases
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Psoriasis
Primary: Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12. — 8; 171; 170 Participants — p=<0.001
Parkinson Disease
Primary: Adverse Effects Experienced — 29; 43 number of events
HIV Infections
Primary: Mean Change From Baseline CD4+ Cell Count — 8.62; 2.68; 8.68; 21.87 Cells/microlitre — p=<0.01
Pain · Multiple Sclerosis
Primary: Change From Baseline in Mean Pain Box Scale-11 Score at 3 Weeks. — -1.3; -0.9 units on a scale — p=0.332
Rheumatoid Arthritis
Primary: Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 14 — 28; 16; 27; 25 Participants — p=0.051
Coronary Calcification
Primary: Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular…
Common Cold
Primary: Investigator's End of Study Assessment of Treatment — 163; 149 participants — p=0.0096
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Plasma Amprenavir (APV) AUC (0-tau[τ]) — 26.6; 64.51; 54.2; 26.22 Hr per microgram/milliliter (hr*µg/mL)
Refractive Error
Primary: Front Surface Lens Deposits — 27; 32; 28; 23 Participants